Coherus Oncology (CHRS) Receivables - Net (2013 - 2026)

Coherus Oncology has disclosed Receivables - Net across 13 years of filings, most recently posting $13.9 million for Q2 2026.

• In Q2 2026, Receivables - Net rose 171.7% year-over-year to $13.9 million; the TTM figure through Jun 2026 stood at $13.9 million (up 171.7% YoY), while the FY2025 annual figure was $17.8 million, down 84.0% from the prior year.
• Receivables - Net came in at $13.9 million for Q2 2026 at Coherus Oncology, down from $22.1 million in the prior quarter.
• In the past five years, Receivables - Net ranged from a high of $260.5 million in Q4 2023 to a low of $5.1 million in Q2 2025.
• Average Receivables - Net over 5 years is $110.5 million, with a median of $110.6 million recorded in 2022.
• Year-over-year, Receivables - Net plunged 97.08% in 2025 and jumped 171.7% in 2026.
• Over 5 years, Receivables - Net stood at $110.0 million in 2022, then soared by 136.92% to $260.5 million in 2023, then sank by 57.27% to $111.3 million in 2024, then tumbled by 84.0% to $17.8 million in 2025, then decreased by 22.08% to $13.9 million in 2026.
• Per Business Quant data, the three most recent Receivables - Net figures were $13.9 million in Q2 2026, $22.1 million in Q1 2026, and $17.8 million in Q4 2025.